eISSN 2329-0358


Welcome to the Annals of Transplantation

Dr. Thomas E. Starzl, "father of organ transplantation", dies at 90
Thomas E. Starzl, MD, PhD, died peacefully Saturday, March 4, 2017, at his home in Pittsburgh. He was born March 11, 1926, in LeMars, Iowa, the second son of Roman Frederick Starzl and Anna Laura (nee Fitzgerald) Starzl. His parents were the first generation American offspring of Czechoslovakian and Irish immigrants.
This... read more

Published: 2017-03-28

The Impact of Donor-Specific Anti-Human Leukocyte Antigen (HLA) Antibody Rebound on the Risk of Antibody Mediated Rejection in Sensitized Kidney Transplant Recipients

Kyo Won Lee, Jae Berm Park, Chan Woo Cho, Nuri Lee, Heejin Yoo, Kyunga Kim, Hyojun Park, Eun Suk Kang, Wooseong Huh, Sungjoo Kim

(Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea)

Ann Transplant 2017; 22:166-176

DOI: 10.12659/AOT.902266

BACKGROUND: Donor-specific anti-HLA antibody (DSA) detected on Luminex-based single antigen assay (LSA) has become the subject of desensitization based upon the results of previous studies. We retrospectively investigated the impact of preoperative DSA on the incidence of antibody mediated rejection (AMR) in patients desensitized using a protocol based on rituximab and rabbit antithymocyte globulin (rATG).
MATERIAL AND METHODS: Nine patients (Group 1, 9/327, 2.8%) were complement dependent cytotoxicity crossmatch (CDC-XM) positive and underwent desensitization with rituximab (375 mg/m²), intravenous immunoglobulin (IVIG; 400 mg/kg), plasmapheresis, and rATG. Twenty-two patients (Group 2, 22/327, 6.7%) were CDC-XM negative but DSA positive on LSA and had received desensitization with rituximab and rATG, while 55 patients (Group 3, 55/327, 16.8%) were CDC-XM and DSA negative with a calculated panel reactive antibody (cPRA) ≥50%. Another 241 patients (Group 4, 241/327, 73.7%) were CDC-XM and DSA negative with a cPRA <50%.
RESULTS: Recipients with DSA (Group 2) experienced more AMR than other groups (p<0.01). More de novo DSAs also developed in Group 2 (p<0.001). The mean fluorescence intensity (MFI) of DSA of patients with AMR tended to rebound (p=0.01).
CONCLUSIONS: Patients who were CDC-XM negative but DSA positive status were at a higher risk of developing AMR even though they had received desensitization with rATG and rituximab. A more intense desensitization protocol is needed for these recipients. Patients with MFI rebound of DSA should be carefully monitored for the risk of AMR.

Keywords: Desensitization, Immunologic, Graft Rejection, HLA Antigens, Kidney Transplantation

Related Articles (0)

Coming Soon...

Published: 2017-03-24

Early Chimerism After Liver Transplantation Reflects the Clinical Course of Recurrent Hepatitis C

Masashi Utsumi, Akinobu Takaki, Yuzo Umeda, Kazuko Koike, Stephanie C. Napier, Nobukazu Watanabe, Susumu Shinoura, Ryuichi Yoshida, Daisuke Nobuoka, Tetsuya Yasunaka, Takahiro Oto, Motoo Araki, Kazuhide Yamamoto, Toshiyoshi Fujiwara, Takahito Yagi

Ann Transplant 2017; 22:156-165

DOI: 10.12659/AOT.900494

Published: 2017-03-21

Relationships Between Clinical, Self-Reported, and Donation Specific Outcomes: A Prospective Follow-up St...

Käthe B. Meyer, Anders Hartmann, Geir Mjøen, Marit H. Andersen

Ann Transplant 2017; 22:148-155

DOI: 10.12659/AOT.902330